CDKN1B and cancer: While there are no SKP2 inhibitors currently under clinical trials, preclinical assessment of SKP2 inhibitors using in vitro and in vivo cancer models [208,210,211,212] supports their potential for therapeutic reactivation of p27 and induction of cell-cycle arrest in cancers.